Irish biopharma Amarin Corp. PLC, whose R&D base is Stonington, said its fourth-quarter loss increased to $15.4 million on higher expenses.
The loss amounted to 27 cents per diluted share, up from a loss of $10.6 million, or 30 cents, a year ago.
Amarin had no reported revenue in 2012. Its triglyceride drug Vascepa hit the market in 2013. The drug provided $10.1 million in revenue in the recent quarter.
For the year, Amarin lost $166.2 million, compared with $179.2 million in 2012.
